{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:35:44Z","timestamp":1767339344354,"version":"3.40.5"},"reference-count":62,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2023,6,3]]},"DOI":"10.1080\/13543784.2023.2219387","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T13:07:56Z","timestamp":1685192876000},"page":"537-552","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":46,"title":["The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs"],"prefix":"10.1080","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7201-9163","authenticated-orcid":false,"given":"Elisa","family":"Camela","sequence":"first","affiliation":[{"name":"Dermatology Unit, Istituto Dermopatico Dell\u2019immacolata IDI-IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-0592","authenticated-orcid":false,"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0064-1874","authenticated-orcid":false,"given":"Gabriella","family":"Fabbrocini","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4827-2892","authenticated-orcid":false,"given":"Sabatino","family":"Pallotta","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Istituto Dermopatico Dell\u2019immacolata IDI-IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1803-2046","authenticated-orcid":false,"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2113872"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111574"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312793"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3386"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S328460"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111563"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00504-0"},{"key":"cit0008","unstructured":"International Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque Psoriasis. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02762994?cond=BCD-085&draw=2&rank=6 (last access Jan 22 2023)."},{"key":"cit0009","unstructured":"An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis (BCD-085-7). Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03390101?cond=BCD-085&draw=2&rank=7 (last access Jan 15 2023)."},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00554-4"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17628"},{"issue":"5","key":"cit0012","first-page":"S8","volume":"14","author":"Papp KA","year":"2021","journal-title":"J Clin Aesthet Dermatol"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21743"},{"key":"cit0014","unstructured":"A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3). Availble from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03556202 (last access Jan 29 2023)."},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806382"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12929"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.03.059"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14018"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13702"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13745"},{"key":"cit0023","unstructured":"Efficacy of Roflumilast in the Treatment of Psoriasis (PSORRO). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04549870?cond=roflumilast&draw=17&rank=35 (last access last access 28 2023)."},{"key":"cit0024","unstructured":"Roflumilast Versus Methotrexate in Psoriasis. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05684744?cond=roflumilast&draw=4&rank=24 (last access Jan 19 2023)."},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60803-5"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.01.056"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.030"},{"key":"cit0028","unstructured":"Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03540160 (last access Jan 2, 2023)."},{"key":"cit0029","unstructured":"Safety and Efficacy Study of CF101 to Treat Psoriasis. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00428974?cond=cf-101&draw=2&rank=10 (last access Jan 11, 2023)."},{"key":"cit0030","unstructured":"Trial of CF101 to Treat Patients With Psoriasis. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01265667?cond=cf-101&draw=2&rank=4 (last access Jan 12, 2023)."},{"key":"cit0031","unstructured":"CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03168256?cond=cf-101&draw=2&rank=2&view=record (last access Feb 9 2023)."},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01801-4"},{"key":"cit0033","unstructured":"An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05200247?cond=spesolimab&draw=2&rank=5 (last access Jan 9 2023)."},{"key":"cit0034","first-page":"27","volume":"38","author":"Erdes S","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05545-y"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0273340"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13800"},{"key":"cit0038","unstructured":"A Safety Study of Mirikizumab (LY3074828). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01947933?cond=mirikizumab&draw=3&rank=19 (last access Jan 18 2023)."},{"key":"cit0039","unstructured":"A Study of Mirikizumab in Participants With Plaque Psoriasis. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03718884?cond=mirikizumab&draw=4&rank=3 (last access Jan 12 2023)."},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106642"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221664"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw1736"},{"key":"cit0043","unstructured":"A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04772079?cond=deucravacitinib&draw=3&rank=12 (last access Jan 29, 2023)."},{"key":"cit0044","unstructured":"Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05478499?cond=deucravacitinib&draw=2&rank=6 (last access Jan 17, 2023)."},{"key":"cit0045","unstructured":"An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05124080?cond=deucravacitinib&draw=3&rank=15 (last access Feb 5, 2023)."},{"key":"cit0046","unstructured":"A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05633264?cond=deucravacitinib&draw=2&rank=1 (last access Jan 12, 2023)."},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00878-9"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215164"},{"key":"cit0049","first-page":"e22843","volume":"14","author":"Naseem S","year":"2022","journal-title":"Cureus"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.58347\/tml.2023.1668b"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1057083"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61039-4"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2019.1638910"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27123680"},{"key":"cit0055","unstructured":"Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT\u2122 Study in Moderate to Severe Psoriasis. Available from: https:\/\/www.businesswire.com\/news\/home\/20220629005222\/en\/%C2%A0Can-Fite-Announces-Positive-Top-Line-Results-from-Piclidenoson-Phase-III-COMFORT%E2%84%A2-Study-in-Moderate-to-Severe-Psoriasis (last access Jan 12, 2023)."},{"key":"cit0056","unstructured":"A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic Impairment. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05376839 (last access Jan 7, 2023)."},{"key":"cit0057","unstructured":"A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05044234 (las las 12, 2023)."},{"key":"cit0058","first-page":"7","volume":"526","author":"Clebak KT","year":"2023","journal-title":"FP Essent"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2173171"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2089020"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2153593"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15941"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2023.2219387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T15:23:01Z","timestamp":1690644181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2023.2219387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,3]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,3]]}},"alternative-id":["10.1080\/13543784.2023.2219387"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2023.2219387","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"type":"print","value":"1354-3784"},{"type":"electronic","value":"1744-7658"}],"subject":[],"published":{"date-parts":[[2023,6,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-03-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}